Gontero Paolo, Birtle Alison, Capoun Otakar, Compérat Eva, Dominguez-Escrig José L, Liedberg Fredrik, Mariappan Paramananthan, Masson-Lecomte Alexandra, Mostafid Hugh A, Pradere Benjamin, Rai Bhavan P, van Rhijn Bas W G, Seisen Thomas, Shariat Shahrokh F, Soria Francesco, Soukup Viktor, Wood Robert, Xylinas Evanguelos N
Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
Eur Urol. 2024 Dec;86(6):531-549. doi: 10.1016/j.eururo.2024.07.027. Epub 2024 Aug 17.
This publication represents a summary of the updated 2024 European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ. The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation.
For the 2024 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences.
Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients' risk stratification and treating them appropriately.
This overview of the 2024 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. These guidelines are designed for effective integration into clinical practice.
本出版物是2024年欧洲泌尿外科学会（EAU）非肌层浸润性膀胱癌（NMIBC）、TaT1期肿瘤及原位癌指南更新内容的总结。除非另有说明，本文所提供的信息仅限于尿路上皮癌。目的是针对NMIBC的临床管理提供实用建议，重点关注临床表现。
对于2024年NMIBC指南，通过对文献进行结构化评估来识别、整理和评估新的相关证据。检索的数据库包括Medline、EMBASE和Cochrane图书馆。指南中的建议由专家组制定，以优先考虑临床重要的护理决策。每项建议的强度根据替代管理策略的利弊平衡、证据质量（包括估计的确定性）以及患者价值观和偏好的性质及变异性来确定。
主要建议强调对NMIBC患者进行全面诊断、治疗和随访的重要性。指南强调定义患者风险分层并进行适当治疗的重要性。
本2024年EAU指南概述为NMIBC的危险因素、诊断、分类、预后因素、治疗和随访提供了有价值的见解。这些指南旨在有效融入临床实践。
